



LMW

MAIL STOP AMENDMENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: S.H. Kleven et al. Attorney Docket No.: UGRF125155
Application No.: 10/520,833 Art Unit: 1642
Filed: July 29, 2005 Confirmation No.: 9350
Title: MYCOPLASMA GALLISEPTICUM FORMULATION

SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Seattle, Washington 98101

November 1, 2006

TO THE COMMISSIONER FOR PATENTS:

Applicants are aware of the information listed in the attached form that may be material to the prosecution of the above-identified patent application.

1. X Copies of the listed publications are enclosed for the Examiner's use.
2. X A concise explanation of the relevance of document Cite No. F5 (which is not in the English language), as presently understood by the individual designated under 37 C.F.R. § 1.56(c) most knowledgeable about its content, is provided in the accompanying EPO search report indicating the degree of relevance.
3. X A concise explanation of the relevance of documents Cite Nos. F6 and F7 (which are not in the English language), as presently understood by the individual designated under 37 C.F.R. § 1.56(c) most knowledgeable about their content, is provided in an English abstract appended to each of said documents.
4. X Pursuant to 37 C.F.R. § 1.97(b), this Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits.
5. X Pursuant to 37 C.F.R. § 1.704(d), this Information Disclosure Statement is accompanied by a statement that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart application. Such communication was received by an individual designated in 37 C.F.R. § 1.56(c) on October 3, 2006, which is not more than thirty days prior to the filing of this Information Disclosure Statement.

6. X The Commissioner is hereby authorized to charge any fees which may be required or credit any overpayment to Deposit Account No. 03-1740.

Respectfully submitted,

CHRISTENSEN O'CONNOR
JOHNSON KINDNESS^{PLLC}



Verne A. Luckow, Ph.D.
Registration No. 45,950
Direct Dial No. 206.695.1645

I hereby certify that this correspondence is being deposited with the U.S. Postal Service in a sealed envelope as first-class mail with postage thereon fully prepaid and addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the below date.

Date: November 1, 2006 Jeffrey Harbert

VAL:jh



MAIL STOP AMENDMENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: S.H. Kleven et al. Attorney Docket No.: UGRF125155
Application No.: 10/520,833 Art Unit: 1642 / Confirmation No.: 9350
Filed: July 29, 2005
Title: MYCOPLASMA GALLISEPTICUM FORMULATION

CERTIFICATION STATEMENT UNDER 37 C.F.R. § 1.704(d)

November 1, 2006

TO THE COMMISSIONER FOR PATENTS:

1. I, the person signing below, state that each item of information contained in the accompanying information disclosure statement was first cited in a (any) communication from a foreign patent office in a counterpart foreign application and this communication was not received by any individual designated in 37 C.F.R. § 1.56(c) more than thirty days prior to the filing of this information disclosure statement.
2. I, the person signing below, am the attorney who prepared or prosecuted the application, or signing on the basis of the information supplied by another individual designated in 37 C.F.R. § 1.56(c).

Respectfully submitted,

CHRISTENSEN O'CONNOR
JOHNSON KINDNESS^{PLLC}

Verne A. Luckow, Ph.D.
Registration No. 45,950
Direct Dial No. 206.695.1645

I hereby certify that this correspondence is being deposited with the U.S. Postal Service in a sealed envelope as first-class mail with postage thereon fully prepaid and addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the below date.

Date: November 1, 2006
VAL:jh



SECOND SUPPLEMENTAL LIST OF CITED REFERENCES THAT MAY BE MATERIAL
TO THE PROSECUTION OF THE SUBJECT APPLICATION

Applicants: S.H. Kleven et al. Attorney Docket No.: UGRF125155
Application No.: 10/520,833 Art Unit: 1642 / Confirmation No.: 9350
Filed: July 29, 2005
Title: MYCOPLASMA GALLISEPTICUM FORMULATION

U.S. PATENT DOCUMENTS

*Examiner Cite	Kind	Date	
Initials No.	Document No.	Code	(mm/dd/yyyy) Name
None.			

FOREIGN PATENT DOCUMENTS

*Examiner Cite	Kind	Publication Date	Country	English Abstract Provided	Translation Provided
Initial No.	Document No.	Code	(mm/dd/yyyy)		
_____ F2	EP 0 307 976	A1	03/22/1989	EP	
_____ F3	EP 0 692 532	A1	01/17/1996	EP	
_____ F4	GB 1,137,306		12/18/1968	GB	
_____ F5	JP 52 134019		11/09/1977	JP	
_____ F6	JP 07 133295		05/23/1995	JP	X
_____ F7	JP 07 228542		08/29/1995	JP	X

OTHER INFORMATION

(Including Author, Title, Date, Pertinent Pages, Etc.)

*Examiner Cite	
Initial No.	
_____ O2	Marois, C., et al., "Molecular Differentiation of <i>Mycoplasma gallisepticum</i> and <i>Mycoplasma imitans</i> Strains by Pulsed-Field Gel Electrophoresis and Random Amplified Polymorphic DNA," <i>J. Vet. Med. B</i> 48:695-703, 2001.

LAW OFFICES OF
CHRISTENSEN O'CONNOR JOHNSON KINDNESS^{PLLC}
1420 Fifth Avenue
Suite 2800
Seattle, Washington 98101
206.682.8100

_____ O3 Whithear, K.G., "Control of Avian Mycoplasmoses by Vaccination," *Rev. Sci. Tech. Off. Int. Epiz. 15*(4):1527-1553, 1996.

Examiner

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

VAL:jh

LAW OFFICES OF
CHRISTENSEN O'CONNOR JOHNSON KINDNESS^{PLC}
1420 Fifth Avenue
Suite 2800
Seattle, Washington 98101
206.682.8100